Lisata Therapeutics

45 articles about Lisata Therapeutics

• Lisata Therapeutics Announces Participation in InfoSec World 2023

  9/20/2023

  Lisata Therapeutics, Inc. announces that Gregory Berkin, Chief Information Officer at Lisata, will participate at InfoSec World 2023 being held September 25-27, 2023, in Lake Buena Vista, Florida.

• Lisata Therapeutics Announces First Patient Treated in the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Advanced Solid Tumors

  9/12/2023

   Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”) today announced treatment of the first patient in the head and neck squamous cell carcinoma cohort of the BOLSTER trial, by Dr. Alexander N. Starodub, a principal investigator of the study, at The Christ Hospital in Cincinnati, Ohio.

• Lisata Therapeutics Announces Outcome of Interim Futility Analysis for its Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma

  9/6/2023

  Lisata Therapeutics, Inc. announced a positive outcome of the prespecified interim futility analysis for the ASCEND trial, a Phase 2b study evaluating LSTA1, Lisata’s lead investigational product, in combination with standard-of-care gemcitabine/nab-paclitaxel in patients with first-line, metastatic pancreatic ductal adenocarcinoma.

• Lisata Therapeutics Announces Participation in Upcoming Conferences in September 2023

  9/5/2023

  Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, announced that David J. Mazzo, PhD, Chief Executive Officer of Lisata, will present at two upcoming conferences in September.

• Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

  8/14/2023

  Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced its financial results for the second quarter ended June 30, 2023.

• Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Malignant Glioma

  8/8/2023

  Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to LSTA1, the Company’s lead product candidate, for the treatment of malignant glioma.

• Lisata Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14 After Market Trading and to Host Conference Call on Tuesday, August 15 at 8:30 a.m. Eastern Time

  8/7/2023

  Lisata Therapeutics, Inc. announced today that it will report its financial results for the second quarter ended June 30, 2023, on Monday, August 14, 2023, after market trading and will host a conference call at 8:30 a.m. Eastern time the following morning.

• Lisata Therapeutics Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors

  7/11/2023

  Lisata Therapeutics, Inc. today announced that Erkki Ruoslahti, M.D., Ph.D., has decided to retire from its Board of Directors effective today, July 11, 2023.

• Lisata Therapeutics to Present at the GCFF Innovation and Healthcare Virtual Conference

  6/12/2023

  Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, announces its participation in the upcoming GCFF Innovation & Healthcare virtual conference on June 15, 2023.

• Lisata Therapeutics Announces Enhancements to Ongoing Phase 2b ASCEND Trial of LSTA1

  5/24/2023

  Lisata Therapeutics, Inc. today announced protocol changes to the ongoing ASCEND trial, a Phase 2b trial evaluating LSTA1, Lisata’s lead investigational drug, in combination with standard-of-care (“SOC”) gemcitabine/nab-paclitaxel in patients with first-line, metastatic pancreatic ductal adenocarcinoma (“mPDAC”).

• Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

  5/9/2023

  Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provides a business update and reports financial results for the three months ended March 31, 2023.

• Lisata Therapeutics to Host First Quarter 2023 Financial Results Conference Call on Tuesday, May 9th, at 4:30 p.m. Eastern Time

  5/2/2023

  Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”) today announced that the Company will report its financial results for the three months ended March 31, 2023, on Tuesday, May 9, 2023, after the close of trading and will host a conference call at 4:30 p.m. Eastern time.

• Lisata Therapeutics Announces Participation in Upcoming Conferences in May 2023

  4/27/2023

  Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, announced that David J. Mazzo, PhD, Chief Executive Officer of Lisata, will present at three upcoming conferences.

• Lisata Therapeutics Receives $2.2 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program

  4/20/2023

  Lisata Therapeutics, Inc. announced that it has received $2.2 million in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority.

• Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico

  4/19/2023

  Lisata Therapeutics, Inc. announces its participation in the upcoming Sequire Investor Summit to be held April 24-26, 2023, at La Concha Resort in San Juan, Puerto Rico.

• Lisata Therapeutics and WARPNINE Announce First Patient Treated in the iLSTA Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma

  4/18/2023

  Lisata Therapeutics, Inc. and WARPNINE Incorporated today announced the treatment of the first patient in the iLSTA Trial of Lisata’s LSTA1 in combination with standard-of-care chemotherapy and immunotherapy as a first-line treatment in locally advanced non-resectable pancreatic ductal adenocarcinoma (“PDAC”).

• Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

  3/30/2023

  Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provides a business update and reports financial results for the three and twelve months ended December 31, 2022.

• Lisata Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, March 30, 2023, at 4:30 p.m. Eastern Time

  3/23/2023

  Lisata Therapeutics, Inc. today announced that the Company will report its financial results for the three and twelve months ended December 31, 2022, on Thursday, March 30, 2023, after the close of trading and will host a conference call at 4:30 p.m. Eastern time.

• Lisata Therapeutics Announces Participation in Upcoming Conferences in February

  2/1/2023

  Lisata Therapeutics, Inc. today announced that management will present at two upcoming conferences.

• Lisata Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

  11/10/2022

  Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, announced its financial results for the three and nine months ended September 30, 2022 and provided a business update.